



## 2020 Breast Module: All References

Below you will find the topics and their accompanying references for the Breast Surgery module of the General Surgery Continuous Certification Assessment. References that are available open source are indicated with a green star ★ and the entire citation is a link to the open access source. References that are not available open access have a link in their PubMed ID to the abstract.

**Diplomates are neither required nor expected to read all of these references before or during the completion of the assessment.**

### Atypical Ductal Hyperplasia

- Racz JM, Degnim AC. When does atypical ductal hyperplasia require excision? *Surg Oncol Clin N Am*. 2018;27(1):23-32.  
[\[PMID: 29132563\]](#)
- Racz JM, Carter JM, Degnim AC. Lobular neoplasia and atypical ductal hyperplasia on core biopsy: current surgical management recommendations. *Ann Surg Oncol*. 2017;24(10):2848-2854.  
[\[PMID: 28766203\]](#)

### Atypical Lobular Hyperplasia and Lobular Carcinoma *In Situ*

- Racz JM, Carter JM, Degnim AC. Lobular neoplasia and atypical ductal hyperplasia on core biopsy: current surgical management recommendations. *Ann Surg Oncol*. 2017;24(10):2848-2854.  
[\[PMID: 28766203\]](#)
- ★ [Chang Sen LQ, Berg WA, Hooley RJ, Carter GJ, Desouki MM, Sumkin JH. Core breast biopsies showing lobular carcinoma \*in situ\* should be excised and surveillance is reasonable for atypical lobular hyperplasia. \*AJR Am J Roentgenol\*. 2016;207\(5\):1132-1145.](#)  
[\[PMID: 27532153\]](#)
- ★ [Murray M, Luedtke C, Liberman L, Nehhozina T, Akram M, Brogi E. Classic lobular carcinoma \*in situ\* and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision. \*Cancer\*. 2013;119\(5\):1073-1079.](#)  
[\[PMID: 23132235\]](#)
- ★ [Menes T, Rosenberg R, Balch S, Jaffer S, Kerlikowske K, Miglioretti DL. Upgrade of high-risk breast lesions detected on mammography in the Breast Cancer Surveillance Consortium. \*Am J Surg\*. 2014;207\(1\):24-31.](#)  
[\[PMID: 24112677\]](#)
- Dupont WD, Degnim AC, Sanders ME, Simpson JF, Hartmann LC. Risk factors for breast carcinoma in women with proliferative breast disease. In: Bland K, Copeland E, Klimberg VS, Gradishar W, eds. *The Breast: Comprehensive Management of Benign and Malignant Disease*. 5th ed. Elsevier; 2017:264-271.



## 2020 Breast Module: All References

### Axillary Sentinel Lymph Node Biopsy and Lymphadenectomy

- ★ [Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 \(Alliance\) randomized clinical trial. \*JAMA\*. 2017;318\(10\):918-926.](#)  
[PMID: 28898379]
- ★ [Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. \*Lancet Oncol\*. 2010;11\(10\):927-933.](#)  
[PMID: 20863759]
- ★ [Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer \(EORTC 10981-22023 AMAROS\): a randomised, multicentre, open-label, phase 3 non-inferiority trial. \*Lancet Oncol\*. 2014;15\(12\):1303-1310.](#)  
[PMID: 25439688]
- ★ [Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer \(T0-T4, N1-N2\) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 \(Alliance\). \*Ann Surg\*. 2016;263\(4\):802-807.](#)  
[PMID: 26649589]
- ★ [Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 \(Alliance\) clinical trial. \*JAMA\*. 2013;310\(14\):1455-1461.](#)  
[PMID: 24101169]
- [Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy \(SENTINA\): a prospective, multicentre cohort study. \*Lancet Oncol\*. 2013;14\(7\):609-618.](#)  
[PMID: 23683750]

### Breast Cancer During Pregnancy and Lactation

- ★ [Shah NM, Scott DM, Kandagatla P, et al. Young women with breast cancer: fertility preservation options and management of pregnancy-associated breast cancer. \*Ann Surg Oncol\*. 2019;26\(5\):1214-1224.](#)  
[PMID: 30680478]
- ★ [Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. \*Ann Oncol\*. 2013;24\(suppl 6\):vi160-vi170.](#)  
[PMID: 23813932]



## 2020 Breast Module: All References

- Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos MA, Bartsch R. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. *Breast Cancer Res Treat.* 2013;137(2):349-357.  
[PMID: 23242615]

### Breast Cancer, Inflammatory

- ★ [Dawood S, Lei X, Dent R, et al. Survival of women with inflammatory breast cancer: a large population-based study. \*Ann Oncol.\* 2014;25\(6\):1143-51.](#)  
[PMID: 24669011]
- ★ [Yamauchi H, Woodward WA, Valero V, et al. Inflammatory breast cancer: what we know and what we need to learn. \*Oncologist.\* 2012;17\(7\):891-899.](#)  
[PMID: 22584436]

### Breast Cancer, Invasive Carcinoma (Ductal, Lobular, All Variants)

- ★ [Gradishar WJ, Anderson BO, Balassanian R, et al. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. \*J Natl Compr Canc Netw.\* 2018;16\(3\):310-320.](#)  
[PMID: 29523670]
- ★ [Choosing Wisely. Society of Surgical Oncology: Five Things Physicians and Patients Should Question. July 2016.](#)
- ★ [Houssami N, Turner RM, Morrow M. Meta-analysis of pre-operative magnetic resonance imaging \(MRI\) and surgical treatment for breast cancer. \*Breast Cancer Res Treat.\* 2017;165\(2\):273-283.](#)  
[PMID: 28589366]
- ★ [Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. \*J Clin Oncol.\* 2013;31\(19\):2382-2387.](#)  
[PMID: 23690420]
- Pediconi F, Miglio E, Telesca M, et al. Effect of preoperative breast magnetic resonance imaging on surgical decision making and cancer recurrence rates. *Invest Radiol.* 2012;47(2):128-135.  
[PMID: 21934515]
- ★ [Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer \(COMICE\) trial: a randomised controlled trial. \*Lancet.\* 2010;375\(9714\):563-571.](#)  
[PMID: 20159292]
- Hwang N, Schiller DE, Crystal P, Maki E, McCreedy DR. Magnetic resonance imaging in the planning of initial lumpectomy for invasive breast carcinoma: its effect on ipsilateral breast tumor recurrence after breast-conservation therapy. *Ann Surg Oncol.* 2009;16(11):3000-3009.  
[PMID: 19603233]



## 2020 Breast Module: All References

- ★ [Khatcheressian J, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. \*J Clin Oncol\*. 2013;31\(7\):961-965.](#)  
[PMID: 23129741]
- ★ [Montgomery DA, Krupa K, Jack WJ, et al. Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience. \*Br J Cancer\*. 2007;96\(12\):1802-1807.](#)  
[PMID: 17533401]
- ★ [Poleszczuk J, Luddy K, Chen L, et al. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. \*Breast Cancer Res\*. 2017;19\(1\):75.](#)  
[PMID: 28666457]
- ★ [Zhang B, Hurvitz S. Long-term outcomes on neoadjuvant treatment of HER-2-positive breast cancer. \*Clin Adv Hematol Oncol\*. 2016;14\(7\):520-530.](#)  
[PMID: 27379947]

### Breast Nodule

- Calhoun BC, Grobmyer SR, Simpson JF. Benign, high-risk, and premalignant lesions of the breast. In: Bland KI, Copeland EM, Klimberg VS, Gradishar WJ, eds *The Breast: Comprehensive Management of Benign and Malignant Disease*. 5th ed. Elsevier; 2018;116-129.
- ★ [Gradishar WJ, Anderson BO, Balassanian R, et al. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. \*J Natl Compr Canc Netw\*. 2018;16\(3\):310-320.](#)  
[PMID: 29523670]
- Jordan VC. The role of tamoxifen in the treatment and prevention of breast cancer. *Curr Probl Cancer*. 1992;16(3):129-176.  
[PMID: 1582240]

### Breast Pain

- Sasaki J, Geletzke A, Kass RB, Klimberg VS, et al. Etiology and management of benign breast disease. In: Bland KI, Copeland EM, Klimberg VS, Gradishar WJ, eds *The Breast: Comprehensive Management of Benign and Malignant Disease*. 5th ed. Elsevier; 2018:79-92.
- Fonseca MM, Lamb LR, Verma R, Ogunkinle O, Seely JM. Breast pain and cancer: should we continue to work-up isolated breast pain? *Breast Cancer Res Treat*. 2019;177(3):619-627.  
[PMID: 31309396]
- Groen JW, Grosfeld S, Wilschut JA, Bramer WM, Ernst MF, Mullender MM. Cyclic and non-cyclic breast-pain: a systematic review on pain reduction, side effects, and quality of life for various treatments. *Eur J Obstet Gynecol Reprod Biol*. 2017;219:74-93.  
[PMID: 29059585]
- ★ [Goyal A. Breast pain. \*BMJ Clin Evid\*. 2011;2011:0812.](#)  
[PMID: 21477394]



## 2020 Breast Module: All References

### Chemotherapy Principles

- Waks AG, Winer EP. Breast cancer treatment: a review. *JAMA*. 2019;321(3):288-300. [PMID: 30667505]
- Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol*. 2018;19(1):115-126. [PMID: 29175149]
- ★ [von Minckwitz G, Fontanella C. Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit? \*Breast\*. 2013;22\(suppl 2\):S149-S151.](#) [PMID: 24074777]
- ★ [Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guidelines focused update. \*J Clin Oncol\*. 2014;32\(21\):2255-2269.](#) [PMID: 24868023]

### Complex Cystic Breast Mass

- ★ [Athanasίου A, Aubert E, Vincent Salomon A, Tardivon A. Complex cystic breast masses in ultrasound examination. \*Diagn Interv Imaging\*. 2014;95\(2\):169-179.](#) [PMID: 24433921]
- ★ [Rinaldi P, Ierardi C, Costantini M, et al. Cystic breast lesions: sonographic findings and clinical management. \*J Ultrasound Med\*. 2010;29\(11\):1617-1626.](#) [PMID: 20966473]
- ★ [Doshi DJ, March DE, Crisi GM, Coughlin BF. Complex cystic breast masses: diagnostic approach and imaging-pathologic correlation. \*Radiographics\*. 2007;27\(suppl 1\):S53-S64.](#) [PMID: 18180235]

### Ductal Carcinoma *In Situ*

- ★ [Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma \*in situ\*. \*J Clin Oncol\*. 2016;34\(33\):4040-4046.](#) [PMID: 27528719]



## 2020 Breast Module: All References

- ★ [Moran M, Schnitt SJ, Giuliano AE, et al. SSO-ASTRO consensus guideline on margins for breast-conserving surgery with whole breast irradiation in stages I and II invasive breast cancer. \*Int J Radiat Oncol Biol Phys.\* 2014;88\(3\):553-564.](#)  
[PMID: 24521674]

### Genetic Susceptibility

- ★ [Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. \*Genet Med.\* 2015;17\(5\):405-424.](#)  
[PMID: 25741868]

### Genomic Profiling for Treatment Decisions

- ★ [Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. \*N Engl J Med.\* 2018;379\(2\):111-121.](#)  
[PMID: 29860917]
- ★ [Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. \*J Clin Oncol.\* 2006;24\(23\):3726-3734.](#)  
[PMID: 16720680]
- ★ [Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. \*N Engl J Med.\* 2015;373\(21\):2005-2014.](#)  
[PMID: 26412349]
- ★ [Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. \*N Engl J Med.\* 2019;380\(25\):2395-2405.](#)  
[PMID: 31157962]

### Mastectomy, Nipple Sparing

- Smith BL, Tang R, Rai U, et al. Oncologic safety of nipple-sparing mastectomy in women with breast cancer. *J Am Coll Surg.* 2017;225(3):361-365.  
[PMID: 28728962]
- Murphy BL, Hoskin TL, Boughey JC, et al. Outcomes and feasibility of nipple-sparing mastectomy for node-positive breast cancer patients. *Am J Surg.* 2017;213(4):810-813.  
[PMID: 27692794]
- Coopey SB, Tang R, Lei L, et al. Increasing eligibility for nipple-sparing mastectomy. *Ann Surg Oncol.* 2013;20(10):3218-3222.  
[PMID: 23975296]
- Hieken TJ, Boolbol SK, Dietz JR. Nipple-sparing mastectomy: indications, contraindications, risks, benefits, and techniques. *Ann Surg Oncol.* 2016;23(10):3138-3144.



## 2020 Breast Module: All References

[[PMID: 27406096](#)]

- Young WA, Degenim AC, Hoskin TL, et al. Outcomes of > 1300 nipple-sparing mastectomies with immediate reconstruction: the impact of expanding indications on complications. *Ann Surg Oncol*. 2019;26(10):3115-3123.

[[PMID: 31342370](#)]

### Nipple Discharge

- ★ [de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. \*BMJ\*. 2019;365:l1652.](#)

[PMID: 31088823]

- ★ [Istomin A, Masarwah A, Pitkänen M, et al. Galactography is not an obsolete investigation in the evaluation of pathological nipple discharge. \*PLoS One\*. 2018;13\(10\):e0204326.](#)

[PMID: 3029628]

- ★ [de Paula IB, Campos AM. Breast imaging in patients with nipple discharge. \*Radiol Bras\*. 2017;50\(6\):383-388.](#)

[PMID: 29307929]

- ★ [Bodine AM, Holahan B, Mixon A. Benign breast conditions. \*J Am Osteopath Assoc\*. 2017;117\(12\):755-760.](#)

[PMID: 29181518]